chrisvoncsefalvay/vaers-outcomes huggingface dataset:
4 days after vaccine, he ran a fever of 100-102 degrees F on and off for 6 days.  On the 7th day after vaccine, he broke out in severe full-body hives which continued for 5 days.  Treated with BENADRYL.  Decided not to treat with doctor - Recommended steroids.  Also received treatment from Holistic doctor in form of chiropractic adjustment, homeopathic allergy remedy and supplements, and that day he looked much better.
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 19-year-old male patient who received BEXSERO (batch number 154101A, expiry date unknown). On 10th August 2016, the patient received the 1st dose of BEXSERO (intramuscular). On 10th August 2016, 30 min after receiving BEXSERO, the patient experienced injection site pain and injection site warmth. On 11th August 2016, the patient experienced nausea, headache and joint pain. The patient was treated with ibuprofen. On an unknown date, the outcome of the injection site pain, injection site warmth, headache and joint pain were not recovered/not resolved and the outcome of the nausea was recovered/resolved. The reporter considered the injection site pain, injection site warmth, nausea and headache to be related to BEXSERO. It was unknown if the reporter considered the joint pain to be related to BEXSERO. Additional details were provided as follows: The reporter stated that, the patient received BEXSERO at 16:00. Within few hours after vaccination the patient experienced warmness at injection site. By the next morning the patient was slightly nauseated, had headache and the patient was experiencing pain in his joints, specifically hips and knees. The patient was treated with 800 mg ibuprofen last night.
Fever ranging up to 102.8 lasting 36+ hours. Excessive sweating, body chills/aches, dizziness
DEEP VEIN THROMBOSIS UNDER TREATMENT -  I developed Superficial thrombophlebitis and upon Investigation by Doppler Rt Leg at HCF it was discovered that there was  an occlusive Thrombus at Great Saphenous Vein. I am currently being treated by subcut Heparin therapy and will be continuing treatment with oral anti-coagulants. I am also scheduled to have a vascular study to investigate if there are any other thrombi in the limbs.
I am a pharmacist and give shots regularly. The nurse gave the shot way too high on the posterior side of  the shoulder.  It has been 6 months and I am still experiencing intense shoulder pain. Other joints/tendons have also inflamed without any other apparent reason.
Initial misuse report received from a health care professional on 14 October 2013.  A 63 year old patient had received FLUZONE HD. No information was provided regarding the patient. No adverse event was reported. List of documents held by sender: none
Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.  Reporter stated that there had been no power outages that would have impacted the Moderna vaccine. However, the reporter reiterated that because the facility was unable to download the digital data logger, they would need to treat this issue as a temperature excursion. The data logger was unable to download for the months of December-2021, January-2022, and February-2022. They were filling out a temperature excursion assessment with the State currently. Also reported that no adverse reactions were experienced by any patients.
1st covid vaccine 1-13-2021-left arm-one day after injection slight redness/irritation/itching and small amount of bruising, all but bruise resolved within a day, since Wednesday 1-20-2021 left upper arm has been itching, small bruise at injection site remains, reported swelling to left upper arm as well, took benadryl last night, reports a cold pack does help with sxs, no fever, no body aches, no respiratory sxs, no lip/tongue numbness or tingling noted. known HTN, elevated in office, no acute s/s, reports typical to elevate in providers office
Patient developed a tactile fever (per mom) 2 days after receiving the vaccine. The fever waned by days 3-4 post vaccine, and on the evening of day 5, mom noticed "bumps" of rash on the child's neck and chest after her bath. Mom called the morning of day 6 post vaccine, and the child is developing more lesions on her back and near hairline. The bumps are itchy, no vesicular "blisters" yet.
Fatigue, extremity weakness for 1 week; w/u while inpt consisted of lab work and imaging, no treatment.
onset fever, myalgias, fatigue about 24hrs p/inj; loss of appetite, diarrhea;sxs abated some BP inc on BP meds, taking reg has taken no APAP; BP 200/98, T100.2-adv see PMD, APAP
lactating; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPOSURE VIA BREAST MILK (lactating) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013M20A and 013M20A) for COVID-19 vaccination.     No medical history was provided by the reporter.    On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced EXPOSURE VIA BREAST MILK (lactating). At the time of the report, EXPOSURE VIA BREAST MILK (lactating) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications reported. No treatment reported.   This case was linked to MOD-2021-032368 (Parent-Child Link).   See case MOD-2021-032368 for details regarding the child case.
Area of swelling and redness and itching. Lasting for two days.  Ice applied and antihistamines taken.
p/vax pt exp a fever;pt broke out in a rash & was dx w/varicella;pt was treated w/APAP & DPH;
itching; couple of raised, red spots, redness on her shoulders and back; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (itching) and URTICARIA (couple of raised, red spots, redness on her shoulders and back) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     The patient's past medical history included Autoimmune disorder.    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jan-2021, the patient experienced PRURITUS (itching) and URTICARIA (couple of raised, red spots, redness on her shoulders and back). At the time of the report, PRURITUS (itching) and URTICARIA (couple of raised, red spots, redness on her shoulders and back) outcome was unknown.            Reporter did not allow further contact; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Client was asked if  interested in being vaccinated for COVID while our team was on outreach.   Reported never being vaccinated before and wanted to receive vaccine today.  Team was unable to find client on Immunisation Registry so vaccine was administered.  After the fact, it was discovered client had previously been vaccinated on 4/26 and 6/7 with Moderna.
Fever of 102.4 approx. 24 hours of receiving booster; Persistent headache for 5 days from booster; This is a spontaneous report received from contactable reporter(s) (Physician). The reporter is the patient.  A 57 year-old male patient received bnt162b2 (BNT162B2), administration date 15Oct2021 (Batch/Lot number: unknown) at the age of 57 years as dose 3 (booster), single for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: Unknown. Not available/provided to reporter at the time of report completion), for Covid-19 immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: Unknown. Not available/provided to reporter at the time of report completion), for Covid-19 immunization. The following information was reported: PYREXIA (non-serious) with onset 16Oct2021, outcome "recovered", described as "Fever of 102.4 approx. 24 hours of receiving booster"; HEADACHE (non-serious) with onset 16Oct2021, outcome "recovered" (21Oct2021), described as "Persistent headache for 5 days from booster". Therapeutic measures were not taken as a result of pyrexia, headache.  Additional information: No known allergies. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medications within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19; Since the vaccination, the patient has not been tested for COVID-19. Adverse event resulted in none of the above.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
8/9/05 noticed injection site beginning to get red and tender. Hard around injection site. 8/10/05 no temp, hives or respiratory problems. Redness (40mmx40mmx60mm), warmth and tenderness at injection site.
she has a very sensitive  immune system; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP), Program ID: The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: IMMUNE SYSTEM DISORDER (non-serious), outcome "unknown", described as "she has a very sensitive  immune system".  Additional information: The patient got all shots from Pfizer and would like to be updated on new booster shots. If it's the Omicron vaccine same with the BA5 and where she can get it.   No Follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
VACCINE SITE LEFT ARM STARTED SWELLING, I HAD A RED MARK AND IT WAS ACHY 9 DAYS LATER. 2 WEEKS AFTER VACCINE I WOKE UP WITH A VERY STIFF HIP AND COULD HARDLY WALK. IT WAS SWOLLEN AND ACHY.
Tingling; Soreness; Pain at the left arm injection site; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA (Tingling), MYALGIA (Soreness) and VACCINATION SITE PAIN (Pain at the left arm injection site) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 007M20A and 044A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Feb-2021, the patient experienced PARAESTHESIA (Tingling), MYALGIA (Soreness) and VACCINATION SITE PAIN (Pain at the left arm injection site). At the time of the report, PARAESTHESIA (Tingling), MYALGIA (Soreness) and VACCINATION SITE PAIN (Pain at the left arm injection site) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant medications were provided No treatment medications were provided. Patient received second dose and experienced no adverse reactions.
Arm soreness for about a week; Fatigue for almost a week; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm soreness for about a week) and FATIGUE (Fatigue for almost a week) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 042120A and 020120A) for COVID-19 vaccination.     No Medical History information was reported.   On 30-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Arm soreness for about a week) and FATIGUE (Fatigue for almost a week). At the time of the report, PAIN IN EXTREMITY (Arm soreness for about a week) and FATIGUE (Fatigue for almost a week) had resolved.            Concomitant product use was not provided by the reporter.  No treatment information was provided.  Patient experienced no adverse event for First dose.
Major symptoms of Vertigo so far for 5 days (and current) - Dizziness, nausea, vomiting, fever/chills, body ache, major headache
Lung pain and inflammation. X-ray revealed "Hazy groundglass opacity at the left lung base projecting over the left anterior sixth rib"
Narrative: 12/31/22 - Pt presented to ED stating he was diagnosed with COVID on 12/24. Pt c/o of continued coughing and fever since diagnosis. He is complaining of non productive cough, sore throat, fever (101F yesterday), sinus/nasal congestion, sneezing, fatigue, weakness, diarrhea (X 2), nausea (yesterday), vomiting X 1, decrease appetite and changes with smell. No associated changes in taste, sweats, chills, CP, abdominal pain. Admits to chronic shortness of breath. Patient was dx with COVID on 12/24/22. Pt admitted to hospital 12/31/22 with primary diagnosis of COVID Pneumonitis and ESRD. (discharged on 1/5/2023) (It was noted Pt was diagnosed with COVID and started outpatient on molnuparvir with no improvement. He continued to have fever, but denied chills. He was evaluated by ED and medical services were contacted for further evaluation and treatment.) HOUSPITAL COURSE: Pt admitted to the floor. dx bilat bibasilar covid pneumonitis. pt had been on po outpt tx. start on remdesivir, and oxygen. steroids not given due to hx of allergy. cont chronic meds. pt with steady improvement over 72 hours and off oxygen. chief issue was weakness. PT consulted- no rehab or home needs noted. pt cont to improve and deemed stable for d/c to home on 1/5/23. wife was updated by phone with progress. Pt discharged 1/5/23 with principal diagnosis of acute hypoxic respiratory failure due to bilat covid pneumonia.
I've estimated the time of injection and reaction.  My reaction occurred within five minutes of the injection.  I had opened my e-reader to read when I was suddenly had a sinking feeling of doom, an increase in my heart rate and began feeling shaky or jittery.  I then started becoming anxious because I remembered similar feelings, though not as sudden or intense, prior to my earlier allergic reaction.  I tried to rest and the feeling of doom disappeared.  But when I stood up and started walking again, my heart began to beat faster and harder and I felt like I was going to pass out.  I didn't, and the nurse checked my pulse, which was fast, but could have easily been due to my anxiety at that point.  I didn't have any other symptoms and went home.  But the nurse suggested that I report my experience to your site.  My heart rate has remained faster than normal since but not at a concerning level.  Yesterday I had pounding headaches if I began walking or standing, but those have resolved today.   I had previously had the J and J vaccine, and two days after that vaccination my arm began itching.  That resolved with 24 hours and my other side effects were that vaccine were routine.
AFTER THE NEW PRIZER BOOSTER SHOT I WOKE UP IN EXTREME PAIN IE: WHOLE BODY INCLUDING ARMS , LEGS, HEADACHE, STOMACH UPSET . THIS LASTED FOR 5 - 6 HOURS.  EXPERIENCED FATIGUE THE WHOLE NEXT DAY.
Nummular induration 2-3 cm X 3-4 days comfort measure.  Advil - resolution of symptoms.
Pt. received BEXSERO-dose 2 within an hour arm became painful and slightly swollen and red-significant pain persisted for more than a week-sx resolved. (No reaction after 1st BEXSERO).
Legs extremely weak and felt like muscles were not functioning well. Knees were buckling while standing. Started about 4 hours after vaccination. Resolved by morning but fatigue continued. It was the exact same sensation felt last March and led to me not being able to get off couch for three weeks. Couldn't get covid testing until weeks after symptoms started and tested negative in March.   Numbness in lips. Lower lip>upper. Started 2 days later. Resolved after gradually improving after 10 days. Fyi had lip injection/filler within the last 2 years. Moderate burning in Rt leg that started the Friday after the vaccine. No redness or edema. Resolved after 10 days.   Severe brain fog and fatigue and buzzing sensation in head. Much worse than baseline. Buzzing sensation was new. Slept all weekend. Improved to baseline after 14 or so days. Had sharp stabbing pains in the back of my head 7 days after the vaccine. Resolved after 3 to 5 days. Never had these sensations before. No history of headaches.  Went to PCP regarding leg pain, worsening brain fog and fatigue from baseline and unequal pupils that had previously resolved about 2 years prior. Pupils were unequal sizes when I woke up on 1/2.  Pupils now back to frequently being different sizes. No diagnosis made with previous episodes that had resolved. Maybe it was reactivated?  Also had visual distortions in left eye that were new on 1/3 that lasted two minutes. No pain associated with this.  Resolved.   Feel close to baseline now but hesitant to get second dose for these reasons.
Information regarding PREVNAR  was received from a healthcare professional regarding a 7 month old male patient who experienced appearing blue when the mother checked on him the nite of vaccination. At 7 months of age, the patient received a dose on 02 Dec 2009. Relevant medical history was not provided. Indication for PREVNAR was immunization. Product was administered on 02 Dec 2009. Dose regimen was 0.5 mL 1 time per day (intramuscular). Concomitant medications were not reported. The mother reported to the physician that her baby appeared blue when the mother checked on him the nite of vaccination (cyanosis) on 02 Dec 2009. The event resolved. No additional information was available at the time of this report.
A nurse reports post vaccine pt had severe pain and redness at injection site. In follow-up, the reporter stated that the pt's also experienced swelling at the injection site. No follow-up was required and the pt recovered. No further info is expected.
I have experienced increased shortness of breath and difficulty in taking a deep breath since shortly after the vaccine.  The problem continues to increase in severity.
This spontaneous report was received from an office manager and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On an unspecified date in 2018, reported as on an unspecified date since 09-JUL-2018, the patient was vaccinated with improperly stored dose of PEDVAXHIB (lot # N024570 with expiration date: 01-MAY-2020) or (lot# N024571 with expiration date: 01-MAY-2020) intramuscularly (dose and frequency were not reported) for prophylaxis. No adverse effects were reported. The vaccine was exposed to a temperature excursion of 47 to 77 degrees Fahrenheit (F) (57 degrees Fahrenheit (F)) for 14 hours. There was no previous temperature excursion. A digital data logger was involved. This is one of several reports from the same reporter. Sender's Comments: US-009507513-1808USA006189.
Information has been received from a physician concerning a 9 year old (also reported as "8 year old") female who on 12-FEB-2002 was vaccinated with the first dose of MMR II.  On 29-MAR-2009 was vaccinated with the second dose of MMR II.  On 16-DEC-2009 the patient experienced mumps (also reported diagnosed as "R parotitis" on 18-DEC-2009).  The patient was afebrile.  On 18-DEC-2009, the patient had the first blood work which showed IgM was <1:10, IgG was 6.71 and serum amylase was 71.  It was unspecified if the patient sought medical attention.  At the time of the report, the outcome was unknown.  No further information is available.
3 days of fever, followed by 4 days of fever with rash/pox. Treated with Tylenol. Fever consistently 104.1 at 4 hour intervals.
body and muscle ache; body and muscle ache; Fever; This case was reported by a other health professional via call center representative and described the occurrence of fever in a female patient who received Herpes zoster (Shingrix) (batch number 7323T, expiry date 6th May 2022) and (batch number 7JK53, expiry date unknown) for prophylaxis.   On 27th August 2020, the patient received the 1st dose of Shingrix. On an unknown date, the dose was an unknown dose. On 29th August 2020, 2 days after receiving Shingrix, the patient experienced fever, general body pain and muscle pain. On an unknown date, the outcome of the fever was recovered/resolved and the outcome of the general body pain and muscle pain were not recovered/not resolved.   It was unknown if the reporter considered the fever, general body pain and muscle pain to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. After receiving the vaccine, the patent had fever.  On 31st August 2020, during morning, the patient was feeling OK. The fever was gone. However, later during the day, the patient contacted them and mentioned she was still having body and muscle ache.  The patient didn't have a good weekend.  No other information was provided. The reporter consent to follow up. The reported batch number 7323T was corrected to 7JK53 as per sales data sheet.